Carson Advisory Inc. Sells 150 Shares of Illumina, Inc. (NASDAQ:ILMN)

Carson Advisory Inc. reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,455 shares of the life sciences company’s stock after selling 150 shares during the quarter. Carson Advisory Inc.’s holdings in Illumina were worth $203,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after buying an additional 2,336,935 shares during the last quarter. Polen Capital Management LLC raised its stake in Illumina by 0.6% during the 3rd quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after acquiring an additional 29,153 shares during the period. Loomis Sayles & Co. L P raised its stake in Illumina by 5.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock worth $550,212,000 after acquiring an additional 208,267 shares during the period. Bank of New York Mellon Corp raised its stake in Illumina by 6.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock worth $500,926,000 after acquiring an additional 225,074 shares during the period. Finally, Barclays PLC raised its stake in Illumina by 120.0% during the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock worth $242,758,000 after acquiring an additional 964,709 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Jacob Thaysen bought 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ILMN shares. Royal Bank of Canada restated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. StockNews.com cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Barclays lifted their price objective on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus price target of $165.10.

Illumina Trading Down 4.9 %

NASDAQ ILMN traded down $6.06 on Friday, hitting $117.93. 2,986,962 shares of the stock were exchanged, compared to its average volume of 1,712,341. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a fifty day moving average price of $130.33 and a two-hundred day moving average price of $127.11. The firm has a market capitalization of $18.78 billion, a P/E ratio of -16.07 and a beta of 1.20. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.08 earnings per share. Research analysts forecast that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.